Innovative Bispecific Nanobody Targeting CD40 and TPBG for Advanced Colon Cancer Therapy

VHH-P439 is a humanized nanobody bispecific antibody fusion construct designed to precisely target the CD40 molecule (CD40) and trophoblast glycoprotein (TPBG). Currently in biological testing, this program represents a novel therapeutic approach for colon cancer. By simultaneously engaging CD40 molecule (CD40) and TPBG, VHH-P439 aims to modulate tumor-associated signaling pathways and enhance immune-mediated anti-tumor effects. With its advanced molecular design and dual targeting mechanism, VHH-P439 holds strong promise as an innovative treatment strategy for patients with colon cancer, an area with significant unmet clinical need.

Licensing Opportunity

VHH-P439 is available for out-licensing and strategic collaborations. We welcome inquiries from partners interested in innovative colon cancer therapeutics targeting CD40 and TPBG.

Development Phase

Modality

VHH-P439 utilizes a bispecific antibody fusion modality, composed of three distinct polypeptides: one heavy chain featuring an anti-TPBG variable region combined with human IgG1 constant domains, one light chain incorporating an anti-TPBG variable region connected to the kappa constant, and a second heavy chain integrating three anti-CD40 single-domain antibodies fused to a human IgG1 Fc segment. By leveraging nanobody technology, VHH-P439 benefits from smaller molecular size, enhanced tissue penetration, and superior stability compared to conventional antibodies. This structural design facilitates efficient tumor infiltration and robust engagement of targets within the tumor microenvironment, offering important advantages for addressing the heterogeneity and immune barriers characteristic of colon cancer.

Target

CD40 and TPBG are validated cell surface molecules implicated in tumorigenesis and immune modulation. CD40, a member of the TNF receptor superfamily, is broadly expressed on antigen-presenting cells and certain malignancies, and orchestrates multiple immune pathways critical for anti-tumor immunity. TPBG, also known as 5T4, is a cell surface glycoprotein selectively upregulated in numerous solid tumors including colon cancer, while showing limited expression in normal adult tissues. The dual targeting of CD40 and TPBG by VHH-P439 enables simultaneous activation of immune responses and direct interference with tumor cell proliferation and survival. Targeting CD40 and TPBG addresses both tumor cell–intrinsic and extrinsic mechanisms, making this strategy a highly attractive therapeutic asset for colon cancer intervention.

Mechanism of Action

VHH-P439 functions by concurrently binding to CD40 and TPBG, enabling modulation of signal transduction critical to tumor progression and immune surveillance. The anti-TPBG component directs the molecule to tumor cells overexpressing this antigen, facilitating targeted delivery. Simultaneously, engagement of CD40 on immune cells via its single-domain antibody modules activates antigen-presenting cells and potentiates T-cell–mediated anti-tumor immunity. This dual mechanism disrupts tumor growth while enhancing the host immune response. Furthermore, nanobody platforms such as VHH-P439 offer future adaptability for the development of bispecific or ADC modalities, further broadening its therapeutic potential in oncology.

Colon Cancer

Colon cancer is a malignancy arising from the epithelial lining of the colon and is among the most prevalent cancers worldwide. Incidence rates are significant in both Western and developing countries, highlighting its global impact. Standard treatments include surgical resection, chemotherapy, radiation, and more recently, molecularly targeted and immunotherapeutic approaches. However, resistance to standard therapies, tumor heterogeneity, and metastatic disease contribute to ongoing challenges, and there remains a distinct need for novel targeted interventions that improve clinical outcomes and quality of life. VHH-P439, through its dual targeting of CD40 and TPBG, offers a potentially transformative strategy by both modulating the tumor microenvironment and directly targeting malignant cells, addressing limitations of current therapies and advancing the field toward more precise and effective colon cancer treatment.